Pharma Pulse 5/17/24: Apple Watch's Afib App certified by FDA, Learning Telehealth Platforms Benefits Pharmacy Students & more
The latest news for pharma industry insiders.
In an interview with Pharm Exec Associate Editor Don Tracy, Tala Fakhouri, Associate Director for Policy Analysis, FDA, discusses the use of artificial intelligence and machine learning in drug development.
Learning Telehealth Platforms Shows Benefit for Pharmacy Students
Pharmacy graduates must be well-equipped to thrive in various settings, especially in the wake of the pandemic as more avenues to patient care services have emerged.
Apple Watch's afib-tracking app certified by FDA for use in clinical studies
The watch’s sensor and software marked the first digital health product to be qualified under the agency’s Medical Device Development Tools program—a voluntary pathway that deems certain technologies as reliable enough to be employed in scientific research without needing additional review.
Johnson & Johnson to Acquire Proteologix, Inc. to Lead in Atopic Dermatitis Treatment
Johnson & Johnson announced that it has entered into a definitive agreement to acquire Proteologix, Inc., a privately-held biotechnology company focused on bispecific antibodies for immune-mediated diseases, for $850 million in cash, with potential for an additional milestone payment.
In a recent Pharmaceutical Commerce Magazine article, our Chief Mission Officer, Amy Niles, highlights how step therapy, also known as ‘fail first,’ is being used by health plans to save money while harming patients.
As the article outlines, step therapy harms patients by delaying much needed care. Because when a patient is prescribed medication by their provider, they shouldn’t have to wait weeks or months to access that treatment. Learn more about this harmful practice, and our call to action for Congress to pass federal legislation to address it.
https://lnkd.in/eXupSzzd
Have news you want us to share in Pharma Pulse? Reach out to Social Media Editor Miranda Schmalfuhs
